What is Leerink Partnrs’ Forecast for MRSN FY2025 Earnings?

Mersana Therapeutics, Inc. (NASDAQ:MRSN) – Stock analysts at Leerink Partnrs dropped their FY2025 earnings estimates for shares of Mersana Therapeutics in a research note issued on Monday, March 3rd. Leerink Partnrs analyst J. Chang now expects that the company will post earnings of ($0.63) per share for the year, down from their prior forecast of ($0.43). The consensus estimate for Mersana Therapeutics’ current full-year earnings is ($0.62) per share. Leerink Partnrs also issued estimates for Mersana Therapeutics’ FY2026 earnings at ($0.18) EPS.

Mersana Therapeutics (NASDAQ:MRSN) last released its quarterly earnings data on Monday, March 3rd. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.05. Mersana Therapeutics had a negative return on equity of 401.37% and a negative net margin of 214.20%. The company had revenue of $16.36 million for the quarter, compared to analyst estimates of $7.71 million.

A number of other research firms have also weighed in on MRSN. Citigroup started coverage on shares of Mersana Therapeutics in a report on Friday, November 15th. They set a “buy” rating and a $5.00 target price on the stock. Wedbush restated an “outperform” rating and set a $4.00 price target on shares of Mersana Therapeutics in a research report on Monday. Finally, William Blair began coverage on Mersana Therapeutics in a research report on Thursday, February 6th. They issued an “outperform” rating on the stock. Two investment analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Mersana Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $4.25.

Mersana Therapeutics Trading Up 5.9 %

Shares of MRSN opened at $0.51 on Wednesday. Mersana Therapeutics has a twelve month low of $0.46 and a twelve month high of $6.28. The stock has a market cap of $62.79 million, a PE ratio of -0.83 and a beta of 1.39. The company has a quick ratio of 2.35, a current ratio of 2.35 and a debt-to-equity ratio of 13.35. The business’s 50-day moving average price is $0.82 and its 200-day moving average price is $1.56.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. US Bancorp DE purchased a new position in Mersana Therapeutics during the 3rd quarter valued at about $31,000. Los Angeles Capital Management LLC raised its holdings in shares of Mersana Therapeutics by 8.1% during the third quarter. Los Angeles Capital Management LLC now owns 189,660 shares of the company’s stock valued at $358,000 after acquiring an additional 14,240 shares in the last quarter. GSA Capital Partners LLP lifted its stake in Mersana Therapeutics by 368.9% in the third quarter. GSA Capital Partners LLP now owns 271,774 shares of the company’s stock worth $514,000 after acquiring an additional 213,814 shares during the period. Intech Investment Management LLC bought a new stake in Mersana Therapeutics in the third quarter valued at $52,000. Finally, HealthInvest Partners AB increased its position in Mersana Therapeutics by 191.3% during the 3rd quarter. HealthInvest Partners AB now owns 538,621 shares of the company’s stock valued at $1,018,000 after purchasing an additional 353,721 shares during the period. 93.92% of the stock is owned by hedge funds and other institutional investors.

About Mersana Therapeutics

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.